Novartis' rollout plans for malaria med for babies Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 8 July, 2025

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

presented by Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

news Shell company Concentra has found its rhythm, with Cargo Therapeutics as its latest buyout target Novartis maps launch of malaria drug for newborns after Swiss approval Singaporean biotech gets China thumbs-up for study of potentially curative HBV cell therapy FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Post-Hoc Live is now available to stream. Catch full episodes on YouTube or listen on Spotify and Apple Podcasts. Be sure to subscribe so you don’t miss what’s next.

endpoints pharma KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask •  Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene Trump's tax cut law expands orphan drug exclusions, could upend 340B program The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

in case you missed it 1. Compromised drug lot impacts Jasper's chronic hives study, stock falls 2. Apogee reports Phase 2 win for eczema drug that could challenge Sanofi’s Dupixent and Lilly’s Ebglyss 3. Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial 4. Roche-backed Chugai taps into longevity field with Pfizer-allied Gero 5. European Commission fines Alchem, closes API ‘cartel’ investigation  6. Tell the Bot to Tell the Bot About the Bot Derek Lowe, In the Pipeline 7.